Aquestive Therapeutics, Inc. (AQST): Capital Expenditures
$562.0K
Year ended 2025-12-31
$584.0K
Trailing 12 months to 2026-06-30
-18.1%
3-year compound annual growth
+1.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $562.0K | +253.5% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $159.0K | -84.0% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $995.0K | -2.8% | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | $1.02M | +12.2% | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | $913.0K | +76.6% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $517.0K | -22.0% | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | $663.0K | -63.7% | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | $1.82M | -11.8% | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | $2.07M | n/a | 2019-03-14, From 2017-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $562.0K | +253.5% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $97.9K | +47.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $518.0K | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | $518.0K | -75.4% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $1.59M | +17.3% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $718.0K | -23.5% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $2.0K | -80.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $79.0K | n/a |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $0 | -100.0% |
Compare AQST, CPIX, XLO, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗